Traditional Chinese Herbal Formula YA3D3 Ameliorates Alzheimer’s Disease-Like Pathology and Cognitive Impairment in APP/PS1 Transgenic Mice

Tian YANG, Jiarui MA, Siyao LIANG, Yuemeng ZHANG, Ling GUO, Wujuan LI, Yuhong LÜ

Acta Academiae Medicinae Sinicae ›› 2026, Vol. 48 ›› Issue (4) : 618-630.

PDF(9072 KB)
Home Journals Acta Academiae Medicinae Sinicae
Acta Academiae Medicinae Sinicae

Abbreviation (ISO4): Acta Academiae Medicinae Sinicae      Editor in chief: Xuetao CAO

About  /  Aim & scope  /  Editorial board  /  Indexed  /  Contact  / 
PDF(9072 KB)
Acta Academiae Medicinae Sinicae ›› 2026, Vol. 48 ›› Issue (4) : 618-630. DOI: 10.3881/j.issn.1000-503X.17127
Original Articles

Traditional Chinese Herbal Formula YA3D3 Ameliorates Alzheimer’s Disease-Like Pathology and Cognitive Impairment in APP/PS1 Transgenic Mice

Author information +
History +

Abstract

Objective To evaluate the effects of the traditional Chinese herbal formula YA3D3 on cognitive impairment and cerebral β-amyloid (Aβ) deposition in APP/PS1 transgenic mice and to determine whether these effects are mediated by up-regulation of the autophagy-related gene 14 (ATG14). Methods Network pharmacology was employed to predict YA3D3 targets.Total antioxidant capacity and hydroxyl free radical scavenging activity were measured in vitro.BV2 microglial cells were infected with short hairpin RNA (shRNA) lentivirus targeting ATG14 (designated as sh-ATG14) and then treated with 0.5 mg/mL of either water-extract (YA3D3-HF) or fermented (YA3D3-MHF) preparation for 24 h.The expression levels of ATG14 and downstream ATG16L1 were assessed by qPCR and Western blot.Sixty-four 3-month-old male APP/PS1 mice were randomly allocated to eight groups (n=8):APP/PS1 model,donepezil,low-,medium-,and high-dose YA3D3-HF,and low-,medium-,and high-dose YA3D3-MHF.All the drugs were administered ad libitum in drinking water for 90 days.Spatial learning and memory were evaluated through the Morris water maze.Cerebral Aβ deposition was quantified by immunofluorescence.Autophagy-related gene expression in the brain tissue was analyzed by qPCR. Results Network pharmacology indicated significant enrichment of YA3D3 targets in autophagy and phosphatidylinositol 3-kinase/protein kinase B signaling pathways.YA3D3-MHF showed stronger antioxidant activity than YA3D3-HF in vitro (P<0.001).In BV2 cells,both preparations reversed ATG14 knock-down-induced down-regulation in the expression of ATG14 and ATG16L1,with YA3D3-MHF being more potent (P=0.003).The animal experiment showed that all the YA3D3 groups exhibited shorter escape latency and more platform crossings than the APP/PS1 model group (all P<0.05),along with reduced Aβ fluorescence intensity (all P<0.001).The efficacy of high-dose YA3D3-MHF was similar to that of donepezil.qPCR confirmed that YA3D3 up-regulated the expression of ATG14 and modulated the expression of downstream autophagy-related genes in the brain tissue (all P<0.05). Conclusions The traditional Chinese herbal formula YA3D3 may up-regulate the expression of ATG14 to slow down Aβ deposition and ameliorate cognitive impairment in APP/PS1 mice,serving as a potential candidate for Alzheimer’s disease intervention.It should be noted that this study has not directly verified the necessity of ATG14 in vivo,and the causal relationship between the in vivo therapeutic efficacy of YA3D3 and the up-regulation of ATG14 requires further confirmation.In addition,this study only verifies the expression regulation of autophagy-related molecules and does not confirm the enhancement of autophagy flux.

Key words

Alzheimer’s disease / traditional Chinese herbal formula / ATG14 / β-amyloid peptide / microbial fermentation

Cite this article

Download Citations
Tian YANG , Jiarui MA , Siyao LIANG , et al . Traditional Chinese Herbal Formula YA3D3 Ameliorates Alzheimer’s Disease-Like Pathology and Cognitive Impairment in APP/PS1 Transgenic Mice[J]. Acta Academiae Medicinae Sinicae. 2026, 48(4): 618-630 https://doi.org/10.3881/j.issn.1000-503X.17127

References

[1]
中国老年保健协会阿尔茨海默病分会. 阿尔茨海默病患者需求洞察报告[EB/OL].(2023-9-20)[2025-10-22]. https://www.adc.org.cn/index.php?m=article&f=browse&categoryID=20.
[2]
Xiao J, Li J, Wang J, et al. 2023 China Alzheimer’s disease:facts and figures[J]. Human Brain, 2023, 2(3):1771.DOI:10.37819/hb.3.1771.
[3]
Nasb M, Tao W, Chen N. Alzheimer’s disease puzzle:delving into pathogenesis hypotheses[J]. Aging Dis, 2024, 15(1):43-73.DOI:10.14336/AD.2023.0608.
[4]
Liu N, Liang X, Chen Y, et al. Recent trends in treatment strategies for Alzheimer’s disease and the challenges:a topical advancement[J]. Ageing Res Rev, 2024, 94:102199.DOI:10.1016/j.arr.2024.102199.
[5]
中华人民共和国卫生健康委员会. 健康中国行动(2019-2030年)[EB/OL].(2019-7-15)[2025-10-22]. https://www.gov.cn/xinwen/2019-07/15/content_5409694.htm.
[6]
Zhou M, Zheng M, Liang S, et al. Inherent potential of mitochondria-targeted interventions for chronic neurodegenerative diseases[J]. Neural Regen Res, 2026, 21(4):1409-1427. DOI:10.4103/NRR.NRR-D-24-01507.
[7]
Qiao J, Wang C, Chen Y, et al. Herbal/natural compounds resist hallmarks of brain aging:from molecular mechanisms to therapeutic strategies[J]. Antioxidants (Basel), 2023, 12(4):920.DOI:10.3390/antiox12040920.
[8]
Hu M, Ying X, Zheng M, et al. Therapeutic potential of natural products against Alzheimer’s disease via autophagic removal of Aβ[J]. Brain Res Bull, 2024, 206:110835.DOI:10.1016/j.brainresbull.2023.110835.
[9]
梁厶爻, 岳昌武. 范式转型与技术整合:天然药物研发的精准化革新[J]. 延安大学学报(医学科学版), 2025, 23(4):1-6,15.DOI:10.19893/j.cnki.ydyxb.2025-0073.
[10]
Hu E, Li Z, Li T, et al. A novel microbial and hepatic biotransformation-integrated network pharmacology strategy explores the therapeutic mechanisms of bioactive herbal products in neurological diseases:the effects of Astragaloside Ⅳ on intracerebral hemorrhage as an example[J]. Chin Med, 2023, 18(1):40.DOI:10.1186/s13020-023-00745-5.
[11]
Chen M, Nguyen TN, Ren X, et al. Structure and activation of the human autophagy-initiating ULK1C:PI3KC3-C1 supercomplex[J]. Nat Struct Mol Biol, 2025, 32(9):1596-1605.DOI:10.1038/s41594-025-01557-x.
[12]
Yuan Y, Liu Y, Hao L, et al. The neuroprotective effects of Liuwei Dihuang medicine in the APP/PS1 mouse model are dependent on the PI3K/Akt signaling pathway[J]. Front Pharmacol, 2023, 14:1188893.DOI:10.3389/fphar.2023.1188893.
[13]
Ma L, Wang J, Zhou R, et al. Traditional Chinese medicine-derived formulations and extracts modulating the PI3K/AKT pathway in Alzheimer’s disease[J]. Front Pharmacol, 2025, 16:1528919.DOI:10.3389/fphar.2025.1528919.
[14]
Tang X, Nagayach A, Wang C. Microglial autophagy in neurogenesis:a new player in Alzheimer’s disease[J]. Neural Regen Res, 2024, 19(12):2573-2574.DOI:10.4103/NRR.NRR-D-23-01962.
[15]
Tao X, Li N, Liu F, et al. In vitro examination of microglia-neuron crosstalk with BV2 cells,and primary cultures of glia and hypothalamic neurons[J]. Heliyon, 2018, 4(8):e00730. DOI:10.1016/j.heliyon.2018.e00730.
[16]
Navakkode S, Kennedy BK. Alpha-ketoglutarate ameliorates synaptic plasticity deficits in APP/PS1 mice model of Alzheimer’s disease[J]. Aging Cell, 2025, 24(11):e70235.DOI:10.1111/acel.70235.
[17]
Yuan Z, Cai K, Li J, et al. ATG14 targets lipid droplets and acts as an autophagic receptor for syntaxin18-regulated lipid droplet turnover[J]. Nat Commun, 2024, 15(1):631.DOI:10.1038/s41467-024-44978-w.
[18]
Zhang H, Ge S, Ni B, et al. Augmenting ATG14 alleviates atherosclerosis and inhibits inflammation via promotion of autophagosome-lysosome fusion in macrophages[J]. Autophagy, 2021, 17(12):4218-4230.DOI:10.1080/15548627.2021.1909833.
[19]
Chau DD, Yu Z, Chan WWR, et al. The cellular adaptor GULP1 interacts with ATG14 to potentiate autophagy and APP processing[J]. Cell Mol Life Sci, 2024, 81(1):323.DOI:10.1007/s00018-024-05351-8.
[20]
Wen QX, Luo B, Xie XY, et al. AP2S1 regulates APP degradation through late endosome-lysosome fusion in cells and APP/PS1 mice[J]. Traffic, 2023, 24(1):20-33.DOI:10.1111/tra.12874.
[21]
Diao J, Liu R, Rong Y, et al. ATG14 promotes membrane tethering and fusion of autophagosomes to endolysosomes[J]. Nature, 2015, 520(7548):563-566.DOI:10.1038/nature14147.
[22]
Rosewood TJ, Nho K, Risacher SL, et al. Pathway enrichment in genome-wide analysis of longitudinal Alzheimer’s disease biomarker endophenotypes[J]. Alzheimers Dement, 2024, 20(12):8639-8650.DOI:10.1002/alz.14308.

Footnotes

利益冲突 所有作者声明无利益冲突

PDF(9072 KB)

Accesses

Citation

Detail

Sections
Recommended

/